CAR-T CELL THERAPY is a type of cancer immunotherapy which is used in the treatment of various hematological cancers/malignancies. It utilizes the patient's own T cell and re-engineered it by developing antigen on its surface which acts against cancer cells and kill them effectively.

1. CAR-T CELL THERAPY – A
MODIFIED IMMUNOTHERAPY
PRESENTED BY:
SANIYA SANOBER
PHARM-D IV YEAR
MRM COLLEGE OF PHARMACY

2. INTRODUCTION
CAR-T CELL THERAPY is a type of cancer immunotherapy treatment that uses
immune cells called T cells that are genetically altered in a lab to enable them in
locating in destroying cancer cells more effectively.

3. CAR-T [ Chimeric antigen receptor-T cell ] :-
 CAR-T cells are the T cells that
have genetically modified to produce an
artificial T cell receptor for use in
immunotherapy.
v Chimeric Antigen Receptors are
receptor proteins that have been
engineered to give T cells the new
ability to target a specific antigen.

4. INDICATIONS
GENERIC NAME BRAND NAME TARGET ANTIGEN TARGET DISEASE
Tisagenlecleucel Kymriah CD19
B cell acute lymphoblastic
leukemia
B cell non Hodgkin lymphoma
Axicabtagene ciloleucel Yescarta CD19
B cell non Hodgkin lymphoma
Follicular lymphoma
Beruxcabtagene autoleucel Tecartus CD19
B cell acute lymphoblastic
leukemia
Mantle cell lymphoma

5. GENERIC NAME BRAND NAME TARGET ANTIGEN TARGET DISEASE
Lisocantagene
maraleucel
Breyanzi CD19
B cell non hodgkin
lymphoma
Idecabtagene vicleucel Abecma BCMA Multiple myeloma
Ciltacabtagene
autoleucel
Carvkyti BCMA Multiple myeloma

6. CAR-T CELL THERAPY PROCEDURE:-

7. MECHANISM

8. PREVENTION
OF
TOXICITIES

9. TIMING AND
MANAGEMENT
OF TOXICITY

10. TIMELINE OF CAR-T FDAAPPROVALS
2017
AXI-CEL(YESCARTA)
approved for adult R/R
LBCL after two lines
OCTOBER 2017
2018
TISA-CEL (KYMRIAH)
approved for adult R/R
LBCL after two lines
May 2018
2019
2019 Research
ongoing
2020
BREXU-CEL(TECARTUS)
approved for adult R/R
MCL JULY 2020
2021
LISO-CEL (BREYANZI)
approved for adult R/R
LBCL after two lines
FEB 2021
2021
AXI-CEL (YESCARTA)
approved for adult
R/R FL after two
lines MARCH 2021
2021
IDE-CEL(ABECMA)
approved R/R MM
after four lines
MARCH 2021
2022
2022
• CILTA-CEL(CARVYTKI)
approved for R/R MM
after four lines FEBRUARY
2022

11. ANNUAL GROWTH RATE OF CAR-T CELL THERAPY

12. CAR-T cell therapy is expensive and effective because of
its unique mechanism of action. The per patient cost of
CAR-T cell therapy could exceed,$1 million [3 crore INR].
4th June 2021 was a historic day for TMH,IIT Bombay
team and cancer care in India as the first CAR-T cell
therapy was done in Bone Marrow Transplant Unit at
ACTREC , TATA MEMORIAL CENTRE IN INDIA.

13. INNOVATIVE IDEA
• Researches can be done by working on
healthy donors T cells and making
additional modifications to the cell,
and it make safe.
• Blood donors not just can donate their
red blood cells, but can also donate
their own t cells and helping other
people to get rid for their cancers.

14. To make this treatment available everywhere and to reduce the cost we need
1.Clinicians familiar with safe CAR-T cell use.
2.Pragmatic regulations
3.Equity access
4.Support of clinical trials
5.Courage to change the practice.

15. THANK YOU
•